Antibody-drug conjugate is named as a drug or biological intervention in 3 clinical trials in our USA, UK and China trial registers, 3 of which are recruiting. Lead sponsors include Adcendo ApS (1), MBrace Therapeutics (1) and Liaoning Cancer Hospital & Institute (1). Registered phases: Phase 1/2 and Phase 2. Conditions studied include Metastatic Soft Tissue Sarcoma; Unresectable Soft Tissue Sarcoma; Cancer.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07657130 | Optimal Application Timing of ADC Drugs for Advanced Breast Cancer (ClinicalTrials.gov ↗) Breast Cancer Females |
Phase 2 | Recruiting |
| NCT06014658 | Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors (ClinicalTrials.gov ↗) Cancer |
Phase 1/2 | Recruiting |
| NCT06797999 | First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma (ClinicalTrials.gov ↗) Metastatic Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma |
Phase 1/2 | Recruiting |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Metastatic Soft Tissue Sarcoma | 1 |
| Unresectable Soft Tissue Sarcoma | 1 |
| Cancer | 1 |
| Breast Cancer Females | 1 |
| Lead sponsor | Trials |
|---|---|
| Adcendo ApS | 1 |
| MBrace Therapeutics | 1 |
| Liaoning Cancer Hospital & Institute | 1 |
| Register | Antibody-drug conjugate trials |
|---|---|
| Clinical trials in USA | 2 |
| Clinical trials in UK | 1 |
| Clinical trials in China | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Antibody-drug conjugate works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Antibody-drug conjugate (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.